Ads
related to: editas stock prices todayget.dtitrader.com has been visited by 10K+ users in the past month
Search results
Why Editas Medicine Stock Is Soaring Today
Motley Fool· 8 months agoWhat happened Shares of Editas Medicine (NASDAQ: EDIT) were soaring 11.2% higher as of 10:41 a.m. ET on Friday after vaulting as much as 24% earlier in...
Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 14%
Simply Wall St. via Yahoo Finance· 1 year agoEditas Medicine, Inc. (NASDAQ:EDIT) shareholders will have a reason to smile today, with the...
Editas Medicine (EDIT) Crossed Above the 20-Day Moving Average: What That Means for Investors
Zacks via Yahoo Finance· 1 year agoEditas Medicine (EDIT) reached a significant support level, and could be a good pick for investors...
Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 10 months agoEditas Medicine, Inc. (NASDAQ:EDIT) Q2 2023 Earnings Call Transcript August 2, 2023 Editas Medicine,...
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 2 years agoEditas (EDIT) delivered earnings and revenue surprises of 7.14% and 19.54%, respectively, for the...
These Analysts Think Editas Medicine, Inc.'s (NASDAQ:EDIT) Sales Are Under Threat
Simply Wall St. via Yahoo Finance· 2 years agoToday is shaping up negative for Editas Medicine, Inc. (NASDAQ:EDIT) shareholders, with the analysts...
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
Zacks via Yahoo Finance· 4 weeks agoEditas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings...
What Makes Editas (EDIT) a New Buy Stock
Zacks via Yahoo Finance· 3 months agoEditas Medicine (EDIT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection...
Wall Street Analysts Believe Editas (EDIT) Could Rally 139%: Here's is How to Trade
Zacks via Yahoo Finance· 2 years agoThe average of price targets set by Wall Street analysts indicates a potential upside of 138.9% in...
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Zacks via Yahoo Finance· 3 weeks agoFor Immediate Release Chicago, IL – May 3, 2024 – Zacks.com announces the list of stocks featured in...
